AChR-blocking antibodies and complement system dynamics: evaluating their interplay and clinical implications in...

Area of Science:

• Neurology
• Immunology
• Autoimmune Diseases

Background:

• Myasthenia gravis (MG) is an autoimmune disorder targeting the neuromuscular junction, primarily the acetylcholine receptor (AChR).
• While AChR-binding antibodies are studied, the role of AChR-blocking antibodies and their link to the complement system in MG are less understood.

Purpose of the Study:

• To investigate the prevalence of AChR-blocking antibodies and their interaction with the complement system in Argentinian MG patients.
• To explore the relationship between AChR-blocking antibodies, complement activation, and disease severity in MG.

Main Methods:

• Studied 75 MG patients with detectable AChR-binding antibodies.
• Assessed AChR-blocking antibodies, complement components (C3, C4, C5a), and clinical severity (ADL, MG Composite scores).
• Performed correlation analyses to determine associations.

Main Results:

• AChR-blocking antibodies were found in 49.3% of patients.
• Higher AChR-blocking antibody titers correlated with lower disease severity.
• Elevated C4 levels in the AChR-blocking antibody-positive group indicated reduced complement activation.

Conclusions:

• AChR-blocking antibodies are prevalent in MG and associated with milder disease.
• Reduced complement activation suggests a potential protective role for these antibodies.
• AChR-blocking antibodies may serve as biomarkers for a milder MG course, warranting further research for improved clinical management.